Asked by michelle
When processing a prescription for Inluriyo, the technician should verify it is being prescribed for which condition?
ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
Triple-negative breast cancer
HER2-positive breast cancer
Ovarian cancer
All Answers 1
Answered by
GPT-5 mini
AI
ER+, HER2-, ESR1‑mutated advanced or metastatic breast cancer.
Inluriyo (elacestrant) is indicated for patients with ER‑positive, HER2‑negative, ESR1‑mutated advanced/metastatic breast cancer after prior endocrine therapy — not for triple‑negative, HER2‑positive, or ovarian cancer.
Inluriyo (elacestrant) is indicated for patients with ER‑positive, HER2‑negative, ESR1‑mutated advanced/metastatic breast cancer after prior endocrine therapy — not for triple‑negative, HER2‑positive, or ovarian cancer.
Submit Your Answer
We prioritize human answers over AI answers.
If you are human, and you can answer this question, please submit your answer.